Early HER2 dysregulation in gastric and oesophageal carcinogenesis

Histopathology

Volumn 61, Issue 5, 2012, Pages 769-776

  Fassan, Matteo ^a   Mastracci, Luca ^b   Grillo, Federica ^b   Zagonel, Vittorina ^c   Bruno, Sara ^b   Battaglia, Giorgio ^c   Pitto, Francesca ^b   Nitti, Donato ^a   Celiento, Tiziana ^b   Zaninotto, Giovanni ^a   Fiocca, Roberto ^b   Rugge, Massimo ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Carcinogenesis; Dysplasia; HER2; Immunohistochemistry; SISH

Indexed keywords

4B5 ANTIBODY; ANTIBODY; ANTIBODY CB11; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ADENOCARCINOMA; CANCER GRADING; CARCINOGENESIS; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SILVER CHROMOGENIC IN SITU HYBRIDIZATION; STOMACH BIOPSY; STOMACH CANCER;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CARCINOMA IN SITU; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GASTRIC MUCOSA; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METAPLASIA; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84868122631     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04272.x     Document Type: Article

References (30)

1. Rugge M, Pennelli G, Pilozzi E et al. Gastritis: the histology report. Dig. Liver Dis. 2011; 43(Suppl. 4); S373-S384.
2. Fiocca R, Mastracci L, Milione M et al. Microscopic esophagitis and Barrett's esophagus: the histology report. Dig. Liver Dis. 2011; 43(Suppl. 4); S319-S330.
3. Cassaro M, Rugge M, Tieppo C et al. Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype. J. Clin. Pathol. 2007; 60; 615-621.
4. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am. J. Gastroenterol. 2010; 105; 493-498.
5. Rugge M, de Boni M, Pennelli G et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment. Pharmacol. Ther. 2010; 31; 1104-1111.
6. Fassan M, Pizzi M, Farinati F et al. Indefinite for dysplasia in the stomach: the role of gastric mucosa atrophy. Am. J. Clin. Pathol. 2012; in press.
7. Zaninotto G, Minnei F, Guirroli E et al. The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results. Dig. Liver Dis. 2007; 39; 18-25.
8. Rugge M, Meggio A, Cataudella G et al. Barrett's esophagus: still much to learn, but 'Yes, we can!'. Am. J. Gastroenterol. 2008; 103; 2944-2946.
9. Rugge M, Fassan M, Battaglia G, Parente P, Zaninotto G, Ancona E. Intestinal or gastric? The unsolved dilemma of Barrett's metaplasia. Hum. Pathol. 2009; 40; 1206-1207.
10. Fassan M, Croce CM, Rugge M. MicroRNAs in precancerous lesions of the gastrointestinal tract. World J. Gastroenterol. 2011; 17; 5231-5239.
11. Fassan M, Volinia S, Palatini J et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int. J. Cancer 2011; 129; 1661-1670.
12. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376; 687-697.
13. Hofmann M, Stoss O, Shi D et al. Assessment of an HER-2 scoring system for gastric cancer: results from a validating study. Histopathology 2008; 52; 797-805.
14. Villanacci V, Rossi E, Grisanti S et al. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. Minerva Gastroenterol. Dietol. 2008; 54; 347-353.
15. Rossi E, Grisanti S, Villanacci V et al. HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J. Cell Mol. Med. 2009; 13; 3826-3833.
16. Rossi E, Villanacci V, Bassotti G et al. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology 2010; 57; 81-89.
17. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in-situ hybridization methods (FISH and SISH). Histopathology 2011; 58; 383-394.
18. Fassan M, Ludwig K, Pizzi M et al. HER2 status in primary and metastatic esophagogastric junction adenocarcinomas. Hum. Pathol. 2012; in press.
19. Hu Y, Bandla S, Godfrey TE et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod. Pathol. 2011; 24; 899-907.
20. Park YS, Hwang HS, Park HJ et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and insitu hybridization: which scoring system should we use? Hum. Pathol. 2012; 43; 413-422.
21. Langer R, Rauser S, Feith M et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double insitu hybridisation and fluorescence insitu hybridisation. Mod. Pathol. 2011; 24; 908-916.
22. García-García E, Gómez-Martín C, Angulo B et al. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology 2011; 59; 8-17.
23. Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59; 822-831.
24. Tafe LJ, Janjigian YY, Zaidinski M et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence insitu hybridization. Arch. Pathol. Lab. Med. 2011; 135; 1460-1465.
25. Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011; 59; 832-840.
26. Rugge M, Fassan M, Pizzi M, Pennelli G, Nitti D, Farinati F. Operative link for gastritis assessment gastritis staging incorporates intestinal metaplasia subtyping. Hum. Pathol. 2011; 42; 1539-1544.
27. Bosman FT, Carneiro F, Hruban RH et al. World Health Organization classification of tumours of the digestive system, 4th edn. Lyon: IARC Press, 2010.
28. Rugge M, Fassan M, Zaninotto G et al. Aurora kinase A in Barrett's carcinogenesis. Hum. Pathol. 2010; 41; 1380-1386.
29. Fassina A, Cappellesso R, Guzzardo V et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod. Pathol. 2012; 25; 86-99.
30. Bartlett JM, Starczynski J, Atkey N et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J. Clin. Pathol. 2011; 64; 649-653.